Tom Online Inc. ADS  (TOMO) Trade Now »     Rate TOMO  -  Discuss TOMO  -  Add to Watch List        

TomoTherapy Inc. (NASDAQ:TOMO), a developer, manufacturer and distributor of the TomoTherapy Hi•Art® treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers, recently announced the company’s results for the second quarter of 2008. Shares of TomoTherapy plunged to a new 52-week low late last week, losing half their value in early trading based on the release of the results of the company’s second quarter, which ended June 30, 2008.

Reported revenue totaled $52 million, a 19 percent year-over-year increase from $43.7 million in the second qu

StreetInsider.com Pre-Open Movers:

TomoTherapy Incorporated (NASDAQ: TOMO) 32% LOWER; sees Q1 revenue of approximately $39 million, and a net loss of approximately $0.12 per diluted share. (Q1 revenue consensus is $56.88 million and EPS consensus is $0.04 profit. TomoTherapy is lowering its annual guidance for 2008. Management now anticipates revenue of $255 million to $290 million and net income per share in the range of $0.14 to $0.33 per diluted share. (FY08 revenue consensus is $302.46 million and EPS consensus is $0.36)

Overstock.com (Nasdaq: OSTK) 30% HIGHER; reports Q1 loss of $0.17.